Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study
Lorenzo Falchi, Helen Ma, Sandra Klein, Jennifer K Lue, Francesca Montanari, Enrica Marchi, Changchun Deng, Hye A Kim, Aishling Rada, Alice T Jacob, Cristina Kinahan, Mark M Francescone, Craig R Soderquist, David C Park, Govind Bhagat, Renu Nandakumar, Daniel Menezes, Luigi Scotto, Lubomir Sokol, Andrei R Shustov, Owen A O'Connor, Lorenzo Falchi, Helen Ma, Sandra Klein, Jennifer K Lue, Francesca Montanari, Enrica Marchi, Changchun Deng, Hye A Kim, Aishling Rada, Alice T Jacob, Cristina Kinahan, Mark M Francescone, Craig R Soderquist, David C Park, Govind Bhagat, Renu Nandakumar, Daniel Menezes, Luigi Scotto, Lubomir Sokol, Andrei R Shustov, Owen A O'Connor
Abstract
Peripheral T-cell lymphomas (PTCLs) are uniquely vulnerable to epigenetic modifiers. We demonstrated in vitro synergism between histone deacetylase inhibitors and DNA methyltransferase inhibitors in preclinical models of T-cell lymphoma. In a phase 1 trial, we found oral 5-azacytidine and romidepsin to be safe and effective, with lineage-selective activity among patients with relapsed/refractory (R/R) PTCL. Patients who were treatment naïve or who had R/R PTCL received azacytidine 300 mg once per day on days 1 to 14, and romidepsin 14 mg/m2 on days 8, 15, and 22 every 35 days. The primary objective was overall response rate (ORR). Targeted next-generation sequencing was performed on tumor samples to correlate mutational profiles and response. Among 25 enrolled patients, the ORR and complete response rates were 61% and 48%, respectively. However, patients with T-follicular helper cell (tTFH) phenotype exhibited higher ORR (80%) and complete remission rate (67%). The most frequent grade 3 to 4 adverse events were thrombocytopenia (48%), neutropenia (40%), lymphopenia (32%), and anemia (16%). At a median follow-up of 13.5 months, the median progression-free survival, duration of response, and overall survival were 8.0 months, 20.3 months, and not reached, respectively. The median progression-free survival and overall survival were 8.0 months and 20.6 months, respectively, in patients with R/R disease. Patients with tTFH enjoyed a particularly long median survival (median not reached). Responders harbored a higher average number of mutations in genes involved in DNA methylation and histone deacetylation. Combined azacytidine and romidepsin are highly active in PTCL patients and could serve as a platform for novel regimens in this disease. This trial was registered at www.clinicaltrials.gov as #NCT01998035.
© 2021 by The American Society of Hematology.
Source: PubMed